<DOC>
	<DOCNO>NCT02138500</DOCNO>
	<brief_summary>This study see PF-06372865 , experimental drug distribute brain one dose PF-06372865 administer orally healthy volunteer subject . The study also evaluate safety tolerability PF-06372865in subject measure level PF-06372865 blood .</brief_summary>
	<brief_title>A Study Examine Distribution PF-06372865 Brain Healthy Volunteers Using Positron Emission Tomography Radioactive Tracer Following Oral Administration One Dose PF-06372865</brief_title>
	<detailed_description />
	<criteria>Healthy male subject female subject nonchildbearing potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy ) . Known suspected sensitivity flumazenil benzodiazepine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PF-06372865</keyword>
	<keyword>phase 1</keyword>
	<keyword>open-label</keyword>
	<keyword>GABA-A receptor occupancy</keyword>
	<keyword>positron emission tomography</keyword>
	<keyword>healthy subject</keyword>
</DOC>